Cellectar Advances Iopofosine Toward Mid-2027 NDA, Reports Q2 Loss and $34M Cash
CLRB sits 18% above its 52-week low of $2.2 on light trading volume (0.2× avg).
Summary
Cellectar reported a Q2 net loss of $6.9 million with $34 million in cash, while advancing its lead drug iopofosine I 131 toward a mid-2027 NDA submission and dosing first patients in a Phase 1b solid tumor trial.
Key Events · Earnings and Guidance · CLRB
-
Q2 Net Loss of $6.9M
Net loss attributable to common stockholders was $6.9 million, or $0.57 per share, compared to $5.4 million, or $3.39 per share, in Q2 2025. R&D expenses rose to $4.6 million from $2.4 million due to new clinical trials.
-
Cash Runway into Q2 2027
Cash and cash equivalents totaled $34.0 million as of June 30, 2026, up from $13.2 million at year-end 2025, reflecting net proceeds of approximately $31.7 million from the May 2026 offering. Management believes this funds operations into Q2 2027.
-
Iopofosine NDA Planned for Mid-2027
Site activation has begun for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia, with first patient dosing expected in early 2027 and an NDA submission planned for mid-2027 under the FDA's Accelerated Approval Program.
-
CLR 125 Phase 1b Initiated
Enrollment and dosing of first patients has begun in the Phase 1b trial of CLR 125 in refractory triple negative breast cancer, marking the first clinical data for the company's solid tumor program.
Analysis · CLRB · Life Sciences
Cellectar's Q2 results confirm a $6.9 million net loss and $34 million in cash, funding operations into Q2 2027. The real news is the regulatory path: site activation has begun for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia, with an NDA submission planned for mid-2027 under the FDA's Accelerated Approval Program. The company also dosed its first patients in the Phase 1b trial of CLR 125 in triple negative breast cancer and presented strong CLOVER WaM data at ASCO 2026, including a 79.2% major response rate. These milestones de-risk the pipeline and extend the cash runway, but the company remains in a going-concern posture with significant dilution already executed in May 2026.
At the time of this filing, CLRB was trading at $2.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $2.20 to $6.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.